• Major PP tasks include donor recruitment, apheresis donation, processing, and storage.
INTRODUCTION TASKS INVOLVED IN PLATELET PRODUCTION AND TRANSFUSION FROM THE U.S. HOSPITAL PERSPECTIVE: TWO PROCESS FRAMEWORKS

METHODS
OBJECTIVES
LIMITATIONS REFERENCES
• Identification of tasks involved in producing and administering conventionally processed (CP) and PR platelets was informed through direct observation of these tasks at a hospital blood donor center as well as discussion with clinical experts and prior work. 4 • Potential impacts of PR vs CP on PP and PA tasks were identified.
• Platelet production (PP) and platelet administration (PA) are complex processes, largely due to pathogen testing.
• Pathogen reduction (PR) is a new technology that has the potential to improve PP efficiency by simplifying these processes. 1 • PR has successfully been used in Europe for over 10 years.
• Changing FDA guidance may increase uptake of PR in the US (Table 1) . 2, 3 o Recent Food and Drug Administration (FDA) guidance, prompted by Zika virus concerns, recommends either PR or additional Zika testing for platelets manufactured in the US. 3 • To develop a framework detailing the tasks involved in PP and PA from the hospital perspective.
• To use this framework to assess the potential impact of PR on PP and PA tasks.
CONCLUSIONS
• This analysis takes the US perspective only and does not draw on European experience.
• Process framework was developed in a time of changing FDA guidance.
• Relative impact of PR is likely to depend on hospital characteristics (e.g., size, specialty).
• The PP framework can be used in hospital operations research to understand the PP and PA processes and potential impacts of changing FDA guidance.
• PR may simplify tasks involved in producing, storing, and ordering platelets.
• This framework can be used to inform an economic model comparing CP to PR.
FUNDING DISCLOSURE
Unfunded preliminary research to inform subsequent work for Cerus Corp. • As of February 2016, FDA recommended Zika testing only for those blood products donated in certain locations considered to be "active" for Zika virus transmission in the US.
RESULTS
• FDA now recommends Zika testing for all donated blood products nationally.
• PR may be used in lieu of Zika testing for platelets.
(no difference between PR and CP)
Steps specific to CP Steps specific to PR
KEY:
• Consider all platelet units the same (no need for special ordering based on specific patient needs)
ADVERSE EVENT MONITORING
